Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma
Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e005478
DOI: 10.1136/jitc-2022-005478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.03.2023. Verfasst von Julie A Tomolonis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Receptors, Tumor Necrosis Factor, Type II, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Robert and Janice McNair Foundation, National Institutes of Health.
Abstract (Originalsprache)
Background
Tumor progression and resistance to therapy in children with neuroblastoma (NB), a common childhood cancer, are often associated with infiltration of monocytes and macrophages that produce inflammatory cytokines. However, the mechanism by which tumor-supportive inflammation is initiated and propagated remains unknown. Here, we describe a novel protumorigenic circuit between NB cells and monocytes that is triggered and sustained by tumor necrosis factor alpha (TNF-α).
Methods
We used NB knockouts (KOs) of TNF-α and TNFRSF1A mRNA (TNFR1)/ TNFRSF1B mRNA (TNFR2) and TNF-α protease inbitor (TAPI), a drug that modulates TNF-α isoform expression, to assess the role of each component in monocyte-associated protumorigenic inflammation. Additionally, we employed NB-monocyte cocultures and treated these with clinical-grade etanercept, an Fc-TNFR2 fusion protein, to neutralize signaling by both membrane-bound (m) and soluble (s)TNF-α isoforms. Further, we treated NOD/SCID/IL2Rγ(null) mice carrying subcutaneous NB/human monocyte xenografts with etanercept and evaluated the impact on tumor growth and angiogenesis. Gene set enrichment analysis (GSEA) was used to determine whether TNF-α signaling correlates with clinical outcomes in patients with NB.
Results
We found that NB expression of TNFR2 and monocyte membrane-bound tumor necrosis factor alpha is required for monocyte activation and interleukin (IL)-6 production, while NB TNFR1 and monocyte soluble TNF-α are required for NB nuclear factor kappa B subunit 1 (NF-κB) activation. Treatment of NB-monocyte cocultures with clinical-grade etanercept completely abrogated release of IL-6, granulocyte colony-stimulating factor (G-CSF), IL-1α, and IL-1β and eliminated monocyte-induced enhancement of NB cell proliferation in vitro. Furthermore, etanercept treatment inhibited tumor growth, ablated tumor angiogenesis, and suppressed oncogenic signaling in mice with subcutaneous NB/human monocyte xenografts. Finally, GSEA revealed significant enrichment for TNF-α signaling in patients with NB that relapsed.
Conclusions
We have described a novel mechanism of tumor-promoting inflammation in NB that is strongly associated with patient outcome and could be targeted with therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
- Medical Scientist Training Program (MSTP), Baylor College of Medicine, Houston, Texas, USA.
- Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA lsmeteli@texaschildrens.org.
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
- Center for Cell and Gene Therapy, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Xin Xu, Kshiti H Dholakia, Leonid S Metelitsa
Förderung
- NCI NIH HHS
- Robert and Janice McNair Foundation
- National Institutes of Health
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Tomolonis, J. A., Xu, X., Dholakia, K. H., Zhang, C., Guo, L., Courtney, A. N., Wang, S., Balzeau, J., Barragán, G. A., Tian, G., Di Pierro, E. J., & Metelitsa, L. S. (2023). Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma. Journal for ImmunoTherapy of Cancer, 11(3), e005478. https://doi.org/10.1136/jitc-2022-005478
Vancouver
Tomolonis JA, Xu X, Dholakia KH, Zhang C, Guo L, Courtney AN, et al. Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma. Journal for ImmunoTherapy of Cancer. 2023;11(3):e005478. doi:10.1136/jitc-2022-005478
BibTeX
@article{Tomolonis2023,
author = {Tomolonis, Julie A and Xu, Xin and Dholakia, Kshiti H and Zhang, Chunchao and Guo, Linjie and Courtney, Amy N and Wang, Siyue and Balzeau, Julien and Barragán, Gabriel A and Tian, Gengwen and Di Pierro, Erica J and Metelitsa, Leonid S},
title = {Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {3},
pages = {e005478},
doi = {10.1136/jitc-2022-005478}
}
EUVIMED